Posted by Michael Wonder on 21 Oct 2024
Elevar Therapeutics announces FDA acceptance of new drug application resubmission for rivoceranib in combination with camrelizumab as a first-line systemic treatment for unresectable hepatocellular carcinoma
21 October 2024 - FDA sets a PDUFA target action date of 20 March 2025.
Elevar Therapeutics today announced the US FDA accepted the resubmission of a new drug application for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, a PD-1 inhibitor, as a first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma.
